JERUSALEM, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) — LipoMedix, a clinical-stage, oncology-focused pharmaceutical company involved in the development of innovative, safe and effective cancer therapy based on a pegylated liposomal drug delivery platform, today announced that its lead compound, Promitil® (PL-MLP), will be manufactured in the United States by ForDoz Pharma (ForDoz), a privately owned, specialty pharmaceutical company focused on the development, manufacturing, and commercialization of value-added sterile and complex injectable products.
Promitil’s unique formulation is designed for selective delivery of the therapeutic agent to cancer-affected tissues and is ideally suited for cancer chemoradiotherapy. The compound consists of the liposome-based encapsulation of a new chemical entity called Mitomycin-c (MMC) lipidic prodrug (MLP), which is a proprietary prodrug form of the known anticancer agent MMC. In studies, it has been shown to be active against a broad variety of cancer types in animal models, including colorectal, gastric, pancreatic and multi-drug-resistant tumors.
“We continue to move full-steam ahead, knowing that the patients we can help with Promitil have been long awaiting a lower-toxicity and effective treatment option,” said Dr. Alberto Gabizon, President and Chief Scientific Officer of LipoMedix. “We are thinking long term when selecting our partnerships and look forward to partnering with ForDoz as we move toward Phase II studies to move the development of Promitil forward.”
By leveraging ForDoz’s drug delivery technology and experience, LipoMedix expects to be able to effectively troubleshoot the many industry-wide challenges of product development and manufacturing of nanotechnology.
“ForDoz has a proven track record in manufacturing and in successful commercialization,” said Sanjeev Luther, Executive Chairman of the Board of LipoMedix. “Selecting the right partner for each step of the journey is critical to the strategic process of developing a drug and we believe ForDoz is that partner.”
“Our mission is to ultimately aid in the delivery of innovative medicines that will help people live longer, better and easier lives,” said James He, founder and CEO of ForDoz. “It was immediately apparent that the team at LipoMedix has patients top of mind, and we are proud to partner with them to manufacture Promitil here in the U.S.”
Liposomes are closed lipid vesicles. If liposomes remain long in circulation (e.g., pegylated liposomes), they tend to accumulate in tumors due to the enhanced permeability and retention (EPR) effect. LipoMedix has developed a pegylated liposome delivery platform based on the encapsulation of a new chemical entity (NCE) known as mitomycin-c lipidic prodrug (MLP), a proprietary prodrug form of the anticancer agent mitomycin-c. Promitil® enables the efficient and selective tumor delivery of MLP with rapid activation to a powerful mitomycin-c metabolite. Promitil® has shown low toxicity and is anticipated to be active against a broad variety of cancer types in animal models, including colorectal, gastric, pancreatic and multi-drug-resistant tumors. Promitil® is a highly stable formulation with prolonged storage shelf life of over five years. In phase 1A and 1B clinical studies conducted in over 100 cancer patients, Promitil® has shown a favorable safety profile and reduced toxicity as compared to equivalent doses of mitomycin-c. Encouraging signs of antitumor activity have been observed particularly in combination with radiotherapy.
LipoMedix is a clinical-stage, oncology-focused pharmaceutical company involved in the development of an innovative, safe and effective cancer therapy based on a pegylated liposomal drug delivery platform. The Company was established in order to advance the pharmaceutical and clinical development of a patented new chemical entity prodrug of mitomycin-c and its efficient delivery in liposomes to cancer-affected target organs. This formulation, known as Promitil®, or Pegylated Liposomal Mitomycin-c Prodrug (PL-MLP), is believed to overcome the challenges associated with mitomycin-c toxicity and turns it into a state-of-the-art anti-cancer drug that can potentially become the therapy of choice in a variety of cancers, especially those of the gastrointestinal tract (stomach, pancreas, colorectal). The inventor and scientific founder of LipoMedix is Prof. Alberto Gabizon of Hebrew University – Shaare Zedek Medical Center, who is also the co-inventor and co-developer of Doxil®, the first FDA-approved nano-drug in cancer therapy. As co-developer of Doxil®, Prof. Gabizon is one of the few scientists who is intimately familiar with the successful development and commercialization process for liposomal drugs. For more information, visit http://www.lipomedix.com/.
About Rafael Holdings, Inc.
Rafael Holdings is focused on the development of novel cancer therapies. The company is a significant investor in two clinical-stage oncology companies, Rafael Pharmaceuticals, Inc. and LipoMedix Pharmaceuticals Ltd. Through its wholly-owned Barer Institute subsidiary, the company is developing compounds focused on the regulation of cancer metabolism. The company also holds commercial real estate assets in New Jersey and Jerusalem. For more information, visit rafaelholdings.com.
ForDoz Pharma Corp. is a privately owned, specialty pharmaceutical company focusing on the development, manufacturing and commercialization of value-added sterile and complex injectable products such as liposomes, microspheres, micelles, nanosuspensions and microcrystal-suspensions. ForDoz Pharma is located on a 27-acre campus in the greater Princeton area of New Jersey, a prominent pharmaceutical hub in the United States. The campus is the site of ForDoz Pharma’s R&D labs, cGMP QC and microbiology labs and a fully qualified and validated sterile complex injectable product manufacturing facility which complies with both U.S. and EU cGMP standards. ForDoz Pharma is accelerating and improving traditional drug development processes through its proprietary, particle-based, drug delivery technology platform with particle sizes ranging from 10 nm to several µm. At ForDoz Pharma, we can commercialize products as a CDMO partner via a closed-loop system, from R&D, analytical testing and process scale-up to commercial manufacturing, all from our one campus.
Please visit www.fordozpharma.com for more information.
Safe Harbor Statement
This press release contains forward-looking statements. These statements relate to future events or the company’s future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential” or “continue”, the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward-looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.
Rafael Media Contact: